What is HCPCS code C9142?

C9142 is the HCPCS Level II code for Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg. It falls in Section C (Outpatient PPS (Hospital)) of the 2026 HCPCS Level II code set maintained by CMS.

Is C9142 covered by Medicare?

Medicare coverage status for C9142 is: Special coverage instructions apply. Always confirm current coverage with the payer.

Under Medicare Part B, C9142 is priced as: Statute.

C9142 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Short descriptor: Inj, alymsys, 10 mg

⚠ Terminated HCPCS Level II 2026

Terminated Code

C9142 was terminated as of 2022-12-31 and should not be reported for dates of service after that date. This page is retained for historical reference.

Open C9142 in the app →

Look up C9142 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

C9142 is the HCPCS Level II code for Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg (2026). It belongs to Section C — Outpatient PPS (Hospital). Under Medicare, its coverage status is: Special coverage instructions apply. Part B pricing methodology: Statute.

Classification & CMS Attributes

Section: C: Outpatient PPS (Hospital)
Medicare Coverage: Special coverage instructions apply (code D)
Part B Pricing: Statute (indicator 53)
Type of Service: Medical care
Effective Date: 2023-01-01
Termination Date: 2022-12-31
2026 Maintenance: No change this year

References

Cite This Page

Reference C9142 with the canonical source and edition:

C9142 — Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/C9142

Canonical URL: https://icd10codingpro.com/hcpcs-codes/C9142

C9142 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Classification & CMS Attributes

References

Cite This Page

Related Codes in Section C

Get HCC Mappings, Clinical Summaries, and More